MOHAMMED MIRZA: Open Payments
NPI 1710067822 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,334 in 109 payments from 17 companies in 2025. Trend: 2023 $2,077 · 2024 $2,128 · 2025 $2,334
Food & beverage: $2,329Education: $5
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $394 |
| Janssen Pharmaceuticals, Inc | 11 | $280 |
| E.R. Squibb & Sons, L.L.C. | 12 | $277 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $268 |
| ABBVIE INC. | 17 | $245 |
| Neurocrine BioSciences, Inc. | 8 | $193 |
| Supernus Pharmaceuticals, Inc. | 5 | $193 |
| Lundbeck LLC | 4 | $91 |
| Bausch Health US, LLC | 3 | $74 |
| Vanda Pharmaceuticals Inc. | 2 | $71 |
Products named: COBENFY, CAPLYTA, AUSTEDO XR, VRAYLAR, SPRAVATO, INGREZZA, Qelbree, REXULTI.
Industry payments across MO — which companies pay providers there.
